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A b s t r a c t
Introduction: Whether patients with functional dyspepsia (FD) should re-
ceive Helicobacter pylori (H. pylori) eradication therapy remains controver-
sial. The objective of this trial was to evaluate the effect of H. pylori eradica-
tion therapy on dyspeptic symptoms of patients with FD.
Material and methods: A prospective, randomized, placebo-controlled trial 
of H. pylori eradication for FD was conducted. A  total of 720 FD patients 
diagnosed by Rome III criteria were consecutively enrolled. We randomly as-
signed 186 H. pylori infected patients with FD to receive quadruple therapy 
for 14 days and 173 such patients to receive identical-appearing placebos. 
Severity of abdominal symptoms was assessed with the Glasgow Dyspepsia 
Severity Score (GDSS), and eradication of H. pylori by 13C-urea breath test 
was evaluated during one year.
Results: The rate of eradication of H. pylori infection was 87.1% in the treat-
ment group and 2.9% in the placebo group at 6 weeks (p = 0.001). The mean 
GDSS at 12 months was 4.9 ±2.8 in the treatment group, as compared to 
5.2 ±3.4 in the placebo group (p = 0.064). The scores in both groups were 
lower than those at baseline. According to the intention-to-treat analysis, at 
12 months, there was no significant difference between groups in the rate 
of successful treatment (48.6% in the treatment group and 51.2% in the 
placebo group; p = 0.84). There was no significant difference in mean symp-
tom scores between the two treatment groups at any point during follow-up.
Conclusions: The results of our study provide no evidence that H. pylori 
eradication leads to relief of symptoms 12 months after treatment, and 
there is a need for further studies.
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Introduction
Dyspepsia is a common clinical condition associated with a complex 
of upper gastrointestinal symptoms including: upper centered discom-
fort or pain, feeling of abdominal fullness, early satiety, abdominal dis-
tention and bloating, belching, and nausea. It occurs in approximately 
25% of the population each year, but most affected people do not seek 
medical care [1]. Approximately 25% of patients with dyspepsia have an 
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underlying organic cause. However, up to 75% of 
patients have functional (idiopathic or non-ulcer) 
dyspepsia with no underlying cause on diagnostic 
evaluation. 
Functional dyspepsia (FD), one of the most com-
mon gastrointestinal disorders, has prevalence 
rates of 11% to 29.2% worldwide [2]. According 
to the Rome III criteria, FD is defined as the pres-
ence of one or more of the following: postprandial 
fullness, early satiation, epigastric pain or burning 
and no evidence of structural disease (including 
on upper endoscopy) that is likely to explain the 
symptoms [3]. While patients with these symp-
toms and a negative diagnostic evaluation likely 
have FD, according to the Rome III guidelines, the 
criteria should be fulfilled for the last 3 months 
with symptom onset at least 6 months before di-
agnosis.
Helicobacter pylori (H. pylori) is an important 
risk factor for the development of peptic ulcer 
disease, gastric adenocarcinoma, and primary B 
cell lymphoma of the stomach. A possible role for 
H. pylori in the pathogenesis of gastroesophage-
al reflux disease (GERD) has also been suggested 
in a growing number of studies. The association 
between H. pylori infection and FD is unclear, al-
though a minority of patients (from 1% to 15%) 
may improve after eradication treatment [4, 5]. 
Dyspepsia continuing after treatment of H. pylori 
is more likely the result of GERD or FD. Whether 
patients with FD should receive H. pylori eradica-
tion therapy remains controversial. The present 
study was designed to evaluate the effects of 
H. pylori eradication therapy on dyspeptic symp-
toms of patients with FD. 
Material and methods
Patients
This study was approved by the Ethics Commit-
tee of the Ardabil University of Medical Sciences. 
This was a prospective, randomized, placebo-con-
trolled study. Patients presenting with FD to the 
gastroenterology out-patient clinic of Imam Kho-
meini Hospital in Ardabil, Iran between June 2010 
and October 2013 were recruited for the study. 
Patients who met the following criteria were en-
rolled in this study: (1) aged 18–45 years; (2) a de-
finitive diagnosis of FD defined by Rome III crite-
ria; (3) a positive H. pylori infection using a rapid 
urease test (RUT) and histology; (4) not receiving 
antacids, antibiotics, bismuth, or proton-pump in-
hibitors within the prior 4 weeks; and (5) consent 
to participate in the study.
The exclusion criteria included: (1) use of 
antibiotics, bismuth, or proton-pump inhibitors 
within the prior 4 weeks; (2) a negative H. pylo-
ri infection using RUT or histology; (3) previous 
H. pylori eradication therapy; (4) past H. pylori 
infection; (5) patients with previous gastric sur-
gery; (6) the coexistence of serious concomitant 
illness (e.g., decompensated liver cirrhosis or 
uremia); (7) patients less than 18 or greater than 
45 years of age; (8) presence of ulcer or mass on 
endoscopy; (9) reflux esophagitis; (10) Barrett’s 
esophagus; (11) chronic gastric or duodenal ul-
ceration; (12) duodenal or esophageal erosions; 
(13) cancer; (14) presence of alarm signs (ane-
mia, gastrointestinal bleeding, recurrent vom-
iting, weight loss, and etc.); and (15) pregnant 
women. Physical examination and laboratory 
tests (complete blood cell count, renal and liver 
function, fasting blood glucose, and erythrocyte 
sedimentation rate) were carried out at baseline 
and showed normal results, excluding organic 
diseases. All studied patients signed an informed 
consent form and declared their willingness to 
allow the application of their anonymous data for 
research purposes.
Study design
All of the patients eligible for the study under-
went gastroscopy with conscious sedation. Endo-
scopic samplings were performed with a  Pentax 
EG-2990K Video Gastroscope (Pentax Medical 
Company, Tokyo, Japan) after overnight fasting, 
and biopsies were done at one antral site and one 
corpus site for histological examination (by mod-
ified Giemsa staining), and biopsy at another an-
tral site was performed for RUT (Kimberly-Clark, 
CLO test, Rapid Urease Test Gel, GA 30076-2199 
USA). Patients who were positive in both the RUT 
and histological examination were considered 
suitable candidates for the proposed H. pylori 
eradication therapy. Patients were blinded to this 
study and randomly assigned by an independent 
investigator using a computer-generated random 
number table to one of the two groups, the treat-
ment group or control group. The allocation ratio 
was 1 : 1. 
Given that the best results of H. pylori eradi-
cation in Iran are obtained with 2 weeks of fura-
zolidone-based quadruple therapy or clarithromy-
cin-based quadruple therapy [6], patients in the 
treatment group were administered with ome-
prazole, 20 mg twice daily; amoxicillin, 1000 mg 
twice daily; bismuth subcitrate, 240 mg twice 
daily and clarithromycin, 500 mg twice daily for 
14 days. Patients in the control group were ad-
ministered with placebo antibiotics for 2 week. 
The placebo consisted of similar-looking capsules 
as the treatment drugs. Neither the investigators 
nor the patients were aware of the treatment as-
signments. The patients returned 6 weeks and 3, 
6, 9, and 12 months after the cessation of treat-
ment. Helicobacter pylori eradication was evalu-
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ated by 13C-urea breath test (UBiT-IR300; Otsuka 
Electronics, Osaka, Japan), at least 4 weeks after 
the completion of treatment. The breath test, us-
ing 100 mg of 13C-urea, was performed. Follow-up 
gastroscopy was performed 1 year after H. pylori 
eradication. 
Assessment of dyspepsia after Helicobacter 
pylori eradication
We assessed severity of abdominal symptoms 
using the Glasgow dyspepsia severity score (GDSS) 
[7], which is based on several aspects of dyspep-
sia: firstly, the frequency of dyspepsia symptoms 
and the effect that they have on normal activities 
and ability to work; secondly, the need for con-
sultations with physicians for dyspepsia and the 
need for diagnostic investigations for dyspepsia; 
and thirdly, the need for over-the-counter and pre-
scription medication for dyspepsia. A summary of 
the GDSS is given in Table I. GDSS can range from 
0 to 20, with higher scores indicating more severe 
dyspepsia.
Statistical analysis
The statistical analysis of the data was done 
using SPSS software (Version 19, SPSS Inc, United 
States). The comparison of the continuous vari-
ables was performed with Student’s t test, and for 
the comparison of the categorical variables the c2 
test was used. The Pearson correlation analysis 
was used in the evaluation of the correlation be-
tween scores of the different scales and other rel-
evant variables. The effective rates of symptoms 
were analyzed according to intent-to-treat (ITT) 
methods. A p-value of < 0.05 was considered sta-
tistically significant. The results were expressed as 
means ± standard deviations.
Results
From June 2010 to October 2013, a  total of 
720 patients with FD were enrolled in the cur-
rent study, and 359 FD patients with H. pylori 
infection (54.3% were women; mean age: 36.8 
years) were randomized to the study. We excluded 
381 patients with FD: 13 withdrew their the con-
sent, 142 had abnormal findings on endoscopy, 
187 were negative for H. pylori, and 39 had other 
exclusion criteria. The flow of patients through the 
trial and the reasons for exclusion are presented 
in Figure 1. A total of 186 patients were random-
ly assigned to receive omeprazole and antibiot-
ics (treatment group), and 173 were assigned to 
receive placebo (control group). The two groups 
were well balanced with respect to demographic 
and clinical features. At 12 months, 96.2% of the 
patients in the treatment group (179 of 186) and 
93.6% of the patients in the placebo group (162 of 
173) completed the study.
Urea breath testing showed that 87.1% of the 
patients in the treatment group (162 of 186) were 
negative for H. pylori at 6 weeks, as compared 
with 2.9% of the patients in the placebo group 
(5 of 173) (p = 0.001). At 12 months, the erad-
ication rates for H. pylori in the treatment and 
placebo group were 80.3% (139 of 179) and 4.9% 
(8 of 162), respectively, on the basis of urea breath 
testing (p = 0.001). 
FD patients (Rome III) (n = 720)
Gastroscopy with pathology
+
RUT
Helicobacter pylori (+) included  
in intention-to-treat analysis
(n = 359)
Treatment group  
(n = 186)
179 Patients completed 
the follow-up
Placebo group  
(n = 173)
162 Patients completed 
the follow-up
52 Excluded:
– 39 Owing to exclusion criteria
– 13 Withdrew consent
329 Excluded:
–  142 Abnormal findings on 
gastroscopy
–  187 Helicobacter pylori (–)
Figure 1. Flow of participants through the trial
Table I. Glasgow dyspepsia severity score scale
Dyspeptic symptoms:
Frequency 0–5
Effect on normal activities 0–2
Time off work 0–2
Consultation with physician:
In physician’s office 0–2
Home visits by general practitioner 0–2
Tests for dyspepsia 0–2
Medication for dyspepsia:
Over the counter 0–2
On prescription 0–3 
Total 0–20
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Adverse reactions documented during treat-
ment included: darkening of the tongue and 
stool in 65 cases, nausea in 16 cases, diarrhea in 
18 cases, headache in 9 cases, rash in 5 cases, 
coughing in 3 cases and blurred vision in 4 cases. 
The basic vital signs and routine blood, urine and 
stool tests were normal in all the participants.
The mean baseline GDSS was 12.1 ±2.4 for 
the treatment group and 11.9 ±2.2 for the pla-
cebo group. At 6 months, the score was 6.1 ±3.2 
and 7.4 ±3.9 in the treatment group and placebo 
group, respectively (p = 0.081). The mean GDSS at 
12 months was 4.9 ±2.8 in the treatment group, 
as compared with 5.2 ±3.4 in the placebo group 
(p = 0.064). The scores in both groups were low-
er than those at baseline. According to the inten-
tion-to-treat (ITT) analysis, at 12 months, treat-
ment was successful (defined as the presence of 
no more than mild pain or discomfort) in 48.6% 
of the patients in the treatment group (87 of 179) 
and 51.2% of those in the placebo group (83 of 
162) (p = 0.84). There was no significant differ-
ence in mean symptom scores between the two 
treatment groups at any point during follow-up.
Discussion
Although there are several hypotheses with re-
gard to the role of H. pylori infection in the patho-
genesis of FD, the mechanism remains unclear. 
Helicobacter pylori may cause altered smooth 
muscle dysfunction due to the induction of an 
inflammatory response or by the initiation of an 
antibody response [8]. However, studies have not 
found an association between H. pylori and abnor-
mal gastric motor function in patients with FD [9].
Many studies have tried to show increased 
prevalence of H. pylori in patients with FD, but 
the results have been conflicting. Based on the 
hypothesis that H. pylori has a role in FD, the in-
fection should be more frequent in patients with 
dyspepsia. Indeed, many epidemiological studies 
have tried to show such higher prevalence, but 
the results have been conflicting. In a  popula-
tion-based study of H. pylori infection, the results 
seem to support a role of H. pylori infection in dys-
peptic symptoms [10, 11]. Dyspeptic symptoms 
were reported by 44% of the evaluated popula-
tion. The prevalence of H. pylori infection, evalu-
ated using the urea breath test (UBT), was 72% 
in individuals reporting dyspeptic symptoms and 
64% in the asymptomatic population (p < 0.005). 
The prevalence of H. pylori infection was signifi-
cantly higher in dyspeptic than in asymptomatic 
individuals [11].
The symptomatic benefit of eradicating H. py-
lori in patients with non-ulcer dyspepsia may be 
related to the background prevalence of H. pylo-
ri-related ulcer disease in the population being 
studied. Northern Ireland, southern Ireland, and 
Scotland have high prevalence of H. pylori-related 
ulcer disease. Studies in each of these countries 
have shown a  symptomatic benefit of eradicat-
ing H. pylori in patients with normal endoscopic 
findings. Because of geographic and national dif-
ferences in the causes of both ulcer disease and 
non-ulcer dyspepsia, treatment that is beneficial 
in one country may be ineffective in another [12]. 
A meta-analysis of randomized controlled studies 
with 12-month follow-up found that H. pylori erad-
ication therapy is associated with improvement of 
dyspeptic symptoms in patients with FD, which is 
consistently demonstrated in the Asian (OR = 1.54; 
95% CI: 1.07–2.21), European (OR = 1.49; 95% CI: 
1.10–2.02), and American (OR = 1.43; 95% CI: 
1.12–1.83) populations [13].
In 1998, Blum et al. [14] conducted a  dou-
ble-blind, multicenter trial of patients with H. pylori 
infection and dyspeptic symptoms. Patients were 
randomly assigned to seven days of treatment 
with omeprazole, amoxicillin, and clarithromycin 
or with omeprazole alone and then followed up 
for 1 year. After 12 months, gastritis had healed 
in 75% of the patients in the group given omepra-
zole and antibiotics and in 3% of the patients in 
the omeprazole group (p < 0.001); the respective 
rates of H. pylori eradication were 79% and 2%. In 
the group given omeprazole and antibiotics, the 
rate of treatment success among patients with 
persistent H. pylori infection was similar to that 
among patients in whom the infection was eradi-
cated (26% vs. 31%). There were no significant dif-
ferences between the groups in the quality of life 
after treatment. They concluded that in patients 
with non-ulcer dyspepsia, the eradication of H. py-
lori infection is not likely to relieve symptoms [14].
In 1999, Talley et al. [15] studied the effect of 
H. pylori eradication in patients with non-ulcer 
dyspepsia. They randomly assigned 170 H. pylo-
ri-infected patients with non-ulcer dyspepsia to 
receive twice-daily treatment with omeprazole, 
amoxicillin, and clarithromycin for 14 days and 
167 such patients to receive identical-appearing 
placebos; all patients were then followed through 
regular visits for 12 months. At 12 months, there 
was no significant difference between groups in 
the rate of successful treatment (46% in the ac-
tive-treatment group and 50% in the placebo 
group; p = 0.56). There was also no significant 
difference in the rate of successful treatment at 
12 months between patients who were H. pylori- 
negative and those who were H. pylori-positive 
(48% vs. 49%). The rates of successful treatment 
were also similar when patients were analyzed 
according to the type of dyspepsia (ulcer-like, re-
flux-like, or dysmotility-like) and changes in the 
quality of life. There was no significant associa-
tion between treatment success and histologic 
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improvement in chronic gastritis at 12 months 
(p = 0.68). They found no evidence that curing 
H. pylori infection in patients with non-ulcer dys-
pepsia leads to relief of symptoms [15]. In the 
same year, Talley et al. [16] conducted a  multi-
centre, randomized, double-blind, placebo-con-
trolled trial (ORCHID study) of 278 patients infect-
ed with H. pylori who had FD. Helicobacter pylori 
was eradicated in 85% in the treatment group and 
4% in the placebo group. At 12 months follow-up 
there was no significant difference between the 
proportion of patients treated successfully by in-
tention to treat in the eradication arm (24%, 95% 
confidence interval 17% to 32%) and the propor-
tion of patients treated successfully by intention 
to treat in the placebo group (22%, 15% to 30%). 
Changes in symptom scores and quality of life did 
not significantly differ between the treatment and 
placebo groups [16].
The inflammatory response induced by H. py-
lori may lower the discomfort threshold to gastric 
distension by causing alterations in the enteric or 
central nervous system [8]. However, in at least 
one study, H. pylori positive and negative patients 
with FD had no difference in the perception of me-
chanically induced gastric distension [17]. There is 
evidence from randomized controlled trials that 
eradication of H. pylori results in relief of dys-
pepsia in a minority of patients. However, studies 
have failed to establish a  temporal relationship 
between H. pylori infection and FD, or the associa-
tion of H. pylori with a specific symptom complex 
[8]. Therefore, relief of dyspepsia may reflect other 
factors such as cure of unrecognized peptic ulcer 
disease in patients misdiagnosed with FD.
Previous double-blind, randomized studies 
performed elsewhere in the world have shown 
a  significant benefit in that direction. In 1998, 
McColl et al. [18] performed a  randomized, pla-
cebo-controlled trial comparing the efficacy of 
treatment for 2 weeks with omeprazole, amoxi-
cillin, and metronidazole (160 patients) with that 
of omeprazole alone (158 patients) for resolving 
symptoms of dyspepsia in patients with H. pylori 
infection but no evidence of ulcer disease on up-
per gastrointestinal endoscopy. One month after 
the completion of treatment, 88% of the group 
assigned to receive omeprazole and antibiotics 
had a  negative test for H. pylori, as compared 
with 5% of the group assigned to receive ome-
prazole alone. One year later, dyspepsia had re-
solved in 21% of the group given omeprazole and 
antibiotics, as compared with 7% of the group 
given omeprazole alone (95% confidence interval 
for the difference, 7 to 22%; p < 0.001). Among 
the patients in the group given omeprazole and 
antibiotics, the symptoms resolved in 27% who 
had had symptoms for 5 years or less, as com-
pared with 12% who had had symptoms for more 
than 5 years (p = 0.03). They concluded that in 
patients with H. pylori infection and non-ulcer, or 
functional, dyspepsia, treatment with omeprazole 
and antibiotics to eradicate the infection is more 
likely to resolve symptoms than treatment with 
omeprazole alone [18].
A systematic review of 17 randomized controlled 
trials included 3566 patients with functional dys-
pepsia. Eradication of H. pylori was associated with 
a  small but significant benefit, with treatment of 
14 patients needed to cure 1 case of functional dys-
pepsia (relative risk reduction (RRR) = 10%, 95% CI: 
6–14) [19]. In a subsequent randomized control trial, 
404 patients with functional dyspepsia and H. pylori 
were randomized to treatment of H. pylori or pla-
cebo [19]. At 12-month follow-up, patients treated 
with H. pylori eradication therapy were significantly 
more likely to have symptomatic improvement as 
compared with controls (49% vs. 36%) [19].
Another possibility for evaluating the role of 
H. pylori in FD is to consider symptom improve-
ment resulting from cure of both the infection and 
associated inflammation of the gastric mucosa af-
ter eradication treatment [20]. Functional dyspep-
sia treatment trials, due to suboptimal design or 
unclear presentation of data, have rarely been able 
to provide unequivocal evidence of the efficacy of 
a  given treatment. Based on a  systematic over-
view of published studies, Veldhuyzen van Zanten 
et al. [21] evaluated drug treatment of patients 
with FD (including H. pylori positive individuals) 
and provided guidelines for future trials. Fifty-two 
eligible studies were evaluated. Many studies suf-
fered from important weaknesses in study design 
and execution. Only 5 studies used previously val-
idated outcome measures. They concluded that 
because of suboptimal design and/or unclear 
presentation of the data, none of the trials pro-
vided unequivocal evidence that there is effica-
cious therapy for the treatment of FD [21]. Of the 
16 trials included in the analysis by Talley, eight 
indicated that H. pylori eradication treatment had 
a beneficial effect on FD, but the other eight stud-
ies did not show any important benefit [22].
In conclusion, in this study, we assessed the 
clinical benefits of the eradication of H. pylori 
infection in patients with FD. The results of our 
study provide no evidence that H. pylori eradica-
tion leads to relief of symptoms 12 months after 
treatment, and there is a need for further studies.
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